<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367456</url>
  </required_header>
  <id_info>
    <org_study_id>B1371012</org_study_id>
    <secondary_id>2014-001345-24</secondary_id>
    <secondary_id>BRIGHT MDS&amp;AML1012</secondary_id>
    <nct_id>NCT02367456</nct_id>
  </id_info>
  <brief_title>A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients</brief_title>
  <acronym>BRIGHT 1012</acronym>
  <official_title>AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi center open label Phase 1b study is designed to evaluate the safety, efficacy,
      pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined
      with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome
      (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical
      study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase
      with an AML cohort and an MDS cohort.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission (CR) rate for MDS</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>CR rate - percentage of patients achieving CR as defined by modified IWG criteria (2006) for MDS (Expansion cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR) rate for AML</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>CR rate - percentage of patients achieving CR as defined by ELN (2017) for AML (Expansion cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (Safety lead-in phase)</measure>
    <time_frame>Screening through 28 days following last dose of study drug</time_frame>
    <description>Adverse events as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03), timing, seriousness and relationship to study therapy, and laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.03) and timing (Safety lead-in phase)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>All cycles until progression, a median of 1 year</time_frame>
    <description>Response rate - Percentage of participants achieving complete remission + partial remission as defined by modified IWG criteria (2006) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement</measure>
    <time_frame>All cycles until progression, a median of 1 year</time_frame>
    <description>Hematologic Improvement, as defined by modified IWG criteria (2006) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marrow Complete Response (mCR)</measure>
    <time_frame>All cycles until progression, a median of 1 year</time_frame>
    <description>Marrow Complete Response, as defined by modified IWG criteria (2006) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic Response</measure>
    <time_frame>All cycles until progression, a median of 1 year</time_frame>
    <description>Cytogenetic Response, as defined by modified IWG criteria (2006) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable Disease</measure>
    <time_frame>All cycles until progression, a median of 1 year</time_frame>
    <description>Stable Disease, as defined by modified IWG criteria (2006) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for Azacitidine</measure>
    <time_frame>First 2 weeks of treatment</time_frame>
    <description>Area under the Concentration-Time Curve (ng*h/mL) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for Azacitidine</measure>
    <time_frame>First 2 weeks of treatment</time_frame>
    <description>Maximum Observed Plasma Concentration (ng/mL) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Azacitidine</measure>
    <time_frame>First 2 weeks of treatment</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (hrs) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for PF-04449913</measure>
    <time_frame>First 5 months of treatment</time_frame>
    <description>Area under the Concentration-Time Curve (ng*h/mL) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for PF-04449913</measure>
    <time_frame>First 5 months of treatment</time_frame>
    <description>Maximum Observed Plasma Concentration (ng/mL) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for PF-04449913</measure>
    <time_frame>First 5 months of treatment</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (hrs) (Safety lead-in phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough for PF-04449913</measure>
    <time_frame>First 1 month of treatment</time_frame>
    <description>Minimum plasma concentration following daily dosing to steady state (ng/mL) (Expansion cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>All cycles through end of treatment, a median of 1 year</time_frame>
    <description>QTc interval corrected using Fridericia's Formula (msec) (Safety lead-in phase and Expansion cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>All cycles until death or 24 months from first visit of last patient</time_frame>
    <description>Time from date of first study treatment to date of death due to any cause. Patients last known to be alive without date of death documented will be censored at the date of last contact. (Expansion cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marrow complete remission (MDS Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by modified IWG criteria (2006) (MDS expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission (MDS Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by modified IWG criteria (2006) (MDS expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (MDS Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by modified IWG criteria (2006) (MDS expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial or complete cytogenetic response (MDS Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by modified IWG criteria (2006) (MDS expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic improvement (MDS Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by modified IWG criteria (2006) (MDS expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with incomplete hematologic recovery (AML Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by ELN criteria (2017) (AML expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with partial hematologic recovery (AML Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>CRh is defined as CR but with absolute neutrophil count &gt;500/uL, platelets &gt;50,000/uL, and not qualifying for CR (AML Expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphologic leukemia free state (AML Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by ELN criteria (2017) (AML expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission (AML Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by ELN criteria (2017) (AML expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (AML Expansion cohort)</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>As defined by ELN criteria (2017) (AML expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>Duration of CR defined as duration from date of first achieving CR to date of disease progression after CR, or death due to any cause, whichever occurs first (Expansion cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CR</measure>
    <time_frame>All cycles until progression or 24 months from first visit of last patient</time_frame>
    <description>Duration from date of first dose of study drug to date of CR (Expansion cohorts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (Expansion cohorts)</measure>
    <time_frame>Date of informed consent through 28 days following last dose of study drug</time_frame>
    <description>Type, frequency, severity, timing, and relationship to study therapy of adverse events and laboratory abnormalities (graded by NCI CTCAE v.4.03) (Expansion cohorts)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913 (Glasdegib)</intervention_name>
    <description>Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016
             classification.

          -  MDS patients must have Intermediate (&gt;3 to 4.5 points), High Risk (&gt;4.5 - 6) or Very
             High Risk (&gt;6 points) disease according to the Revised International Prognostic
             Scoring System 2012 (IPSS-R).

          -  Clinical indication for treatment with azacitidine for MDS or AML.

        Exclusion criteria:

          -  Patients with AML who are candidates for standard induction chemotherapy as first line
             treatment.

          -  Patients with known active CNS leukemia.

          -  Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham the Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System: Adult Bone Marrow Transplant Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System, Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Chemotherapy Service</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Oncology Pharmacy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt - Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance (SCCA)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center (UWMC)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen - Campus Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaye Edmonton Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Lori Rackel</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaye Edmonton Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d`Amiens-Picardie - Hopital SUD</name>
      <address>
        <city>Amiens cedex 01</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis (AP-HP) - Service Hematologie Senior</name>
      <address>
        <city>Paris CEDEX 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hopital Lyon Sud- Hematologie</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Tours-Hopital Bretonneau-Centre Regional de cancerologie Henry Kaplan</name>
      <address>
        <city>Tours Cedex 01</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371012&amp;StudyName=A%20STUDY%20OF%20PF%2004449913%20IN%20COMBINATION%20WITH%20AZACITIDINE%20IN%20PATIENTS%20WITH%20PREVIOUSLY%20UNTREATED%20INTERMEDIATE%202%20OR%20HIGH%20RISK%20MYELODYSPLASTIC</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <keyword>CMML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

